• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Baxter International Inc.

    2/25/25 4:41:54 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    POS AM 1 d753291dposam.htm POS AM POS AM

    As filed with the U.S. Securities and Exchange Commission on February 25, 2025

    Registration No. 333-264528

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1

    to

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    BAXTER INTERNATIONAL INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   36-0781620
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

     

    One Baxter Parkway

    Deerfield, Illinois 60015

    (224) 948-2000

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Joel T. Grade

    Executive Vice President and Chief Financial Officer

    Baxter International Inc.

    One Baxter Parkway

    Deerfield, Illinois 60015

    (224) 948-2000

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    With copies to:

     

    Ellen K. Bradford

    Senior Vice President

    and Corporate Secretary

    Baxter International Inc.

    One Baxter Parkway

    Deerfield, Illinois 60015

    (224) 948-2000

     

    Catherine M. Clarkin

    Ari B. Blaut

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, NY 10004

    (212) 558-4000

     

     

    Approximate date of commencement of proposed sale to the public: Not applicable. Removal from registration of securities that were not sold pursuant to the above-referenced registration statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Baxter International Inc. (the “Registrant”) is filing this post-effective amendment to amend the registration statement on Form S-3 (Registration No. 333-264528), filed by the Registrant with the U.S. Securities and Exchange Commission (the “SEC”) on April 28, 2022, and declared effective by the SEC on May 11, 2022 (the “Registration Statement”), registering the offer and sale from time to time of up to $10,000,000,000 of the Registrant’s securities.

    The Registrant has determined that it has obtained well-known seasoned issuer status subsequent to filing the Registration Statement and is now eligible to register its securities under a new registration statement on Form S-3ASR (the “New Registration Statement”). In connection with the Registrant filing the New Registration Statement, all offers and sales of the Registrant’s securities registered pursuant to the Registration Statement are being terminated. Accordingly, pursuant to the undertaking contained in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities which remain unsold at the termination of the offering, the Registrant hereby terminates the Registration Statement in respect of any securities that remain unsold and deregisters all securities that remain unsold under the Registration Statement.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Deerfield, State of Illinois, on February 25, 2025.

     

    BAXTER INTERNATIONAL INC.*
    By:  

    /s/ ELLEN K. BRADFORD

     

    Ellen K. Bradford

     

    Senior Vice President and Corporate Secretary

     

    *

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to the Registration Statement.

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    5/30/2024$36.00Neutral
    Goldman
    More analyst ratings

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Group Pres., ITT & Pharma. Soriano Maria Cecilia was granted 2,273 shares and covered exercise/tax liability with 918 shares, increasing direct ownership by 2% to 56,006 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/11/26 7:11:08 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP and General Counsel Rosenbloom David S. was granted 17,055 shares and covered exercise/tax liability with 5,225 shares, increasing direct ownership by 11% to 119,464 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/11/26 7:10:01 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    EVP,Group Pres,Healthcare Rasul Reazur was granted 18,951 shares and covered exercise/tax liability with 5,770 shares, increasing direct ownership by 10% to 139,846 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/11/26 7:08:56 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and eve

    1/21/26 5:00:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Introduces the Dynamo Series, a New Smart Stretcher to Help Address Common Challenges in Hospital Settings

    Versatile, scalable design allows a range of procedures to be performed in-stretcher, reducing the need for unnecessary patient transfers Integrates advanced, connected technologies to support patient safety and help prevent falls Launching in the U.S. with select geographic expansion planned later this year Baxter International Inc. (NYSE:BAX), an innovator in smart beds for med-surg and the intensive care unit, announced at the 2026 J.P. Morgan Healthcare Conference the upcoming U.S. launch of the Dynamo Series stretcher. The Dynamo Series is a stretcher designed to help alleviate the physical and cognitive burden on care teams1 and make it easier for them to focus on patient ca

    1/13/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Goldman with a new price target

    Goldman downgraded Baxter from Buy to Neutral and set a new price target of $25.00

    8/1/25 8:11:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    Baxter International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Leadership Update, Financial Statements and Exhibits

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    2/12/26 7:17:39 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Baxter International Inc.

    SCHEDULE 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    1/21/26 8:02:11 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Other Events

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    12/22/25 4:59:44 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and eve

    1/21/26 5:00:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

    Baxter International Inc. (NYSE:BAX) ("Baxter" or the "Company") today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes. Title of Security CUSIP Number(1) Principal Amount Outstanding U.S. Treasury Reference Security Bloomberg Reference Page Reference Yield Fixed Spread Early Tender Payment (3)(4) Total Consideration(3)(4) 2.600% Senior Unsecured Notes due 2026 071813BQ1 $750,000,000 UST 1.500% due Aug. 15, 2026 FIT3 3.713% +30 bps $30

    12/4/25 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care